• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Reactants on Vascular System
    9 Drugs classified under this therapeutic system

    All the Therapeutic System Drugs

    Filter by letter: ALL A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
    partial basket chart

    Soluble Guanylate Cyclase Stimulator. Riociguat 0.5, 1, 1.5, 2, 2.5 mg.
    F.C. TABS.: 42×0.5mg, 1mg, 1.5mg, 42, 84×2mg, 84×2.5mg. The recomm. start. dose is 1 mg×3/d for 2 wks. approx. 6 to 8 hrs. apart. incr. by 0.5 mg×3/d every two wks. to a max. of 2.5 ×3/d, if systole. blood press. is ≥95 mmHg and the pt. has no signs or sympt. of hypotens.
    Maint.dose The max. total dly. dose is 7.5 mg i.e., 2.5 mg ×3/d. If a dose is missed, tmt. should be cont. with the next dose as planned. See lit.
    CTEPH, Pts. with WHO Funct. class II to III: Inoperable CTEPH, Persist./ recur. CTEPH after surg. tmt., to improve exercise capacity. PAH: as monother. /combination with endothelin receptor antag., tmt. of adult pts. with PAH with WHO Funct. class II to III to improve exercise capacity. Effic.has been shown in a PAH population including aetiologies of idiopathic or heritable PAH or PAH assoc. with connect. tissue dis.
    C/I: Hypersens. Co-adm. with PDE 5 inhib. (e.g sildenafil, tadalafil, vardenafil). Sev. hep. impair. (Child Pugh C). Co-adm. with nitrates or nitric oxide donors (e.g. amyl nitrite) in any form. Pts. with systolic
    blood pressure < 95 mm Hg at tmt. init.

    partial basket chart

    Hyaluronidase 1,500 IU/dose.
    AMPS: 10, 100. See lit.
    Enhance. permeat. S.C. or I.M. inject.,
    local anesthet., S.C. infus., promot.
    resorpt. excess fluids and blood in tissues.
    C/I: Hypersens., unexplain. prem. labour,
    reduct. swelling of bites, stings, sites
    where infect. or malign. present.

    partial basket chart

    Prostaglandin. Iloprost 0.1 mg/ml.
    AMPS (Conc. sol. for infus.): 0.5 ml.
    See lit.
    Periph. art. occlus. dis. (stage III and IV)
    in adv. arterioscler., diabet. angiopath.,
    thromboangit. obliterans (Buerger’s dis.),
    Raynaud’s syndr.
    C/I: Pregn., lact., hypersens. to compon.,
    where effect of drug on platelets might
    incr. risk of hemorrh., (e.g., active pept.
    ulc., trauma, intracran. hemorrh.), severe
    coron. heart dis., unstable ang., M.I.
    within last 6 mths., acute or chron.
    congest. heart fail., severe arrhyth.
    suspect. pulm. congest.

    not in the basket chart

    Sympathomimetic. Norepinephrine Bitartrate 1 mg/ml.
    AMPS: 10 x 4 ml x 1 mg/ml. See lit.
    BP control in certain acute hypotens.
    states, adjuv. in card. arrest, profound
    C/I: Hypotens. caused by blood vol.
    deficits, messenteric or periph. vasc.
    thromb., during cyclopropane or
    halothane anesth. See lit.

    partial basket chart

    Endothelin Receptor Antagonist. Macitentan 10 mg.
    F.C. TABS.: 30. 10 mg ×1/d, with or without food, should be taken every day at the same time.
    Tmt. of PAH, who GROUP I to delay dis. progress. Dis. progress. includ.: death, initiat. of IV or subcutan. prostanoids, or clin. worsening of PAH (decreased 6-min. walk distance, worsened PAH sympt. and need for additional PAH tmt.). The drug also reduced hospitaliz. for PAH.
    C/I: Hypersens., Soya. Preg., WOCBP who are not using reliable contracep., Lact.
    Pts. with severe hep. impair. (with or without cirrhosis).
    Baseline values of hep. aminotransferases (AST and/or ALT>3×ULN).

    Other therapeutic systems under Cardiovascular System